MTC
TGTX icon

Matrix Trust Company’s TG Therapeutics TGTX Stock Holding History

Matrix Trust Company’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-258
Closed -$9K – 280
2025
Q3 		$9K Sell
258
-60
-19% -$1.98K ﹤0.01% 244
2025
Q2 		$11K Sell
318
-46
-13% -$1.71K ﹤0.01% 252
2025
Q1 		$14K Buy
+364
New +$12.2K ﹤0.01% 230

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Matrix Trust Company's TGTX Position: Q4 2025 in Review

Matrix Trust Company sold out of TG Therapeutics (TGTX) in Q4 2025, closing a stake of 258 shares — an estimated $9K sold.

Matrix Trust Company first reported a position in TGTX in Q1 2025 and held it in 3 quarters. The position peaked at $14K in Q1 2025. 352 funds tracked by Wall St. Rank hold TGTX as of Q4 2025.

  • Matrix Trust Company reported no remaining TG Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Matrix Trust Company sold 258 TG Therapeutics shares in Q4 2025, an estimated $9K.
  • Matrix Trust Company first reported a position in TG Therapeutics in Q1 2025 and held it in 3 quarters.
  • Matrix Trust Company's TG Therapeutics position peaked at $14K in Q1 2025.
  • 352 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2025.

Based on Matrix Trust Company's 13F filing for Q4 2025, filed 13 Jan 2026.